Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Clinical Activity Extension Study of mRNA-3927 in Propionic Acidemia
2022-502911-12-00Phase 2Authorised
- Sponsor
- Moderna Inc
- Start
- Feb 2026
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of mRNA-3927 in propionic acidemia (PA), sponsored by Moderna Inc. Primary endpoint: Incidence and severity of adverse events. Planned start Feb 2026; status: authorised.
02
Drugs
mRNA-3927
03
Conditions
propionic acidemia (PA)
Beyond the preview
Go deeper on 2022-502911-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502911-12-00.